



## Curriculum Vitae

Personal information **Annie George Chandy**

### Work experience

1. Employer: Statens Serum Institute
  - Start date: 022008
  - End date: 022011
  - Position: Research Scientist
  - Activities: Employed as scientist in group focused on vaccine development against genital Chlamydia trachomatis infection.
  - Country: Denmark
2. Employer: Department of Rheumatology and Inflammation Research, Gothenburg University
  - Start date: 042005
  - End date: 012008
  - Position: Post doctoral scientist
  - Activities: Responsible for set\_up and execution of project aiming at enhancing vaccination efficacy against human papilloma virus induced cancer in a mouse model, combined with research in Rheumatology; one study on the importance of oxygen radicals in protection against arthritis in a mouse model and one clinical study on how the cytokines BAFF and APRIL in cerebrospinal fluid can be used as markers of neuropsychiatric involvement in patients with systemic lupus erythematosus.
  - Country: Sweden

### Education and training

1. Subject: Dept of Medical Microbiology and Immunology, Gothenburg University
  - Start date: 061996
  - End date: 062001
  - Qualification: PhD in Immunology and Vaccine Research
  - Organisation: Immunology and Microbiology. Research in basic mechanisms leading to immunity or immunological tolerance.
  - Country: Sweden
2. Subject: Uppsala University
  - Start date: 092007
  - End date: 112007
  - Qualification: Course in clinical trials with applied biostatistics (7.5 credits)
  - Organisation: The regulatory framework around clinical trials. Applied biostatistics.
  - Country: Sweden
3. Subject: Lund University
  - Start date: 021989
  - End date: 121993
  - Qualification: MSc Biology
  - Organisation: Molecular Biology, Immunology, Microbiology
  - Country: Sweden

### Additional information

#### Publications

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. George\_Chandy A, Trysberg E, Eriksson K.Arthritis Res Ther. 2008;10(4):R97. Th17 development and autoimmune arthritis in the absence of reactive oxygen species. George\_Chandy A, Nordström I, Nygren E, Jonsson IM, Postigo J, Collins LV, Eriksson K.Eur J Immunol. 2008;38(4):1118\_26. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Chandy AG, Nurkkala M, Josefsson A, Eriksson K.Vaccine. 2007; 10;25(32):6037\_46. Oral tolerance induction by mucosal administration of cholera toxin B coupled antigen involves T<sub>H</sub> cell proliferation in vivo and is not affected by depletion of CD25+ T cells. George Chandy A, Hultkrantz S, Raghavan S, Czerkinsky C, Lebens M, Telemo E, Holmgren J.Immunology. 2006;118(3):311\_20. Mucosal adjuvants and anti\_infection and anti\_immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George\_Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.Immunol Lett. 2005; 15;97(2):181\_8. Review. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. Anjuère F, George\_Chandy A, Audant F, Rousseau D, Holmgren J, Czerkinsky C.J Immunol. 2003;170(3):1586\_92. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen\_presenting cells. George\_Chandy A, Eriksson K, Lebens M, Nordström I, Schön E, Holmgren J.Infect Immun. 2001; ;69(9):5716\_25. Vaccination with Bordetella pertussis\_pulsed autologous or heterologous dendritic cells induces a mucosal antibody response in vivo and protects against infection. George\_Chandy A, Mielcarek N, Nordström I, Holmgren J, Eriksson K.Infect Immun. 2001; 69(6):4120\_4. Mucosal immunity and tolerance: relevance to vaccine development. Czerkinsky C, Anjuere F, McGhee JR, George\_Chandy A, Holmgren J, Kieny MP, Fujiyashi K, Mestecky JF, Pierrefite\_Carle V, Rask C, Sun JB.Immunol Rev. 1999;170(1):197\_222. Review. Antigen presentation in the murine oral epithelium. Eriksson K, Ahlfors E, George\_Chandy A, Kaiserlian D, Czerkinsky C.Immunology. 1996;88(1):147\_52. Differential in vivo effects of a superantigen and an antibody targeted to the same T cell receptor. Activation\_induced cell death vs passive macrophage\_dependent deletion. Gonzalo JA, Baixeras E, González\_García A, George\_Chandy A, Van Rooijen N, Martínez C, Kroemer G.J Immunol. 1994; 15;152(4):1597\_608.

**Projects** Chairman of the Board and board member of Abarceo Pharma AB, 2017\_2022: Company spun out from Lund University. The mission of the company is to cure or halt the progression of diabetes by treatment with VDAC\_1 targeting molecules. Board member of Lundoeh Diagnostics 2019\_2022: The company is developing blood markers for the diagnosis and prevention of type 2 diabetes. The company has developed a diagnostic test that can predict type 2 diabetes several years before disease onset.

**Memberships**

**Other Relevant Information**